MEDITULIP Co., Ltd. products

More and more cancer patients get chemoport implants rather than get injections repeatedly on peripheral blood vessels, as cancer drugs sometimes damage the small vessels and the surrounding tissue. A chemoport is the most reliable and convenient method of central venous access. MEDITULIP developed TULIP PORT, a chemoport to maximize patient comfort and safety by making the housing thin and small and the septum wide yet pressure-resistant. TULIP PORT is power-injectable and supports X-ray, CT and MRI examinations. Moreover, MEDITULIP uses more expensive, implantable-grade polysulfone material. MEDITULIP received regulatory approval in South Korea and is preparing for regulatory approval of its chemoports in other countries.

MEDITULIP developed a novel asymmetrical linear stapler (NALS) that enables surgeons to take tissue samples for frozen section biopsy from the true resection margin and to confirm the radicality of cancer surgery intraoperatively. MEDITULIP patented this technology and develops other medical devices to advance minimally invasive surgery. MEDITULIP is preparing for regulatory approval of its staplers in South Korea and other countries.